RMTG — Regenerative Medical Technology Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
$0.60m
Enterprise Value
$19.21m
Revenue
$4.11m

Annual income statement for Regenerative Medical Technology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0.055	0.438	1.53	2.41	4.11
Cost of Revenue
Gross Profit	0.011	0.15	0.877	1.68	2.82
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	0.503	10.6	2.72	5.74	4.03
Operating Profit	-0.448	-10.2	-1.18	-3.33	0.081
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-5.9	-12.9	-5.58	-9.81	-5.56
Net Income After Taxes	-5.9	-12.9	-5.58	-9.81	-5.56
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-5.9	-12.9	-5.51	-9.81	-5.56
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-5.9	-12.9	-5.51	-9.81	-5.56
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.631	-1.1	-0.456	-0.578	-0.444
Dividends per Share